How Often Is Kymriah Given?
Kymriah (tisagenlecleucel), a CAR-T cell therapy for certain blood cancers like relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) in children and young adults, or large B-cell lymphoma in adults, is administered as a one-time infusion.[1][2] It does not require repeated dosing to maintain effectiveness. The modified T-cells it produces can persist in the body for months to years, providing ongoing anti-cancer activity without additional infusions.
Why Only One Dose?
Once infused, Kymriah's engineered T-cells multiply and target cancer cells independently. Clinical trials showed durable responses—such as complete remission rates of 51-83% in eligible patients lasting years in some cases—without needing redosing.[2][3] Repeat administration is not approved or recommended by the FDA or Novartis, the manufacturer.
What If the Cancer Returns?
No standard retreatment protocol exists for Kymriah. If relapse occurs after initial response, options include other therapies like allogeneic stem cell transplant, bispecific antibodies (e.g., blinatumomab), or clinical trials. Some studies explore second CAR-T infusions with different targets, but these are investigational and carry risks like cytokine release syndrome (CRS).[4]
How Long Do Effects Last?
Remission duration varies: median relapse-free survival reached 24 months in pediatric ALL trials, with some patients remaining cancer-free beyond 5 years.[2][5] Long-term monitoring is required due to risks like secondary malignancies or infections.
Common Administration Details
- Prep: Apheresis collects patient's T-cells, followed by 3-5 weeks of manufacturing.
- Dosing: Single IV infusion (typically 0.6-6 x 10^8 CAR-positive cells, weight-based).
- Follow-up: Hospital monitoring for 10+ days post-infusion for CRS or neurotoxicity; lifelong B-cell aplasia managed with IVIG.[1]
[1]: FDA Label for Kymriah
[2]: Novartis Kymriah Prescribing Information
[3]: NEJM study on ELIANA trial (2018)
[4]: ClinicalTrials.gov on CAR-T retreatment
[5]: Long-term follow-up data from JULIET trial (Lancet Oncology, 2021)